Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer | Synapse

December 31, 2006Open Access

Ver artículo completo

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer

CLCharles N. LandenUniversity of Virginia WMWilliam M. MerrittGynecologic Oncology Group LMLingegowda S. MangalaThe University of Texas MD Anderson Cancer Center

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

IP injection of siRNA incorporated in DOPC allows intra-tumoral delivery and has therapeutic efficacy in orthotopic ovarian tumors. These findings may have therapeutic implications for siRNA-based strategies.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Landen et al. (Sun,) studied this question.

synapsesocial.com/papers/69dd602580eea7d3f699c32e https://doi.org/https://doi.org/10.4161/cbt.5.12.3468

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Overexpression of Protein Tyrosine Kinases in Human Esophageal Cancer2008 · 126 citations
2RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity2003 · 127 citations
3Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2).2001 · 241 citations
4Antiangiogenic and Antitumor Efficacy of EphA2 Receptor Antagonist2004 · 160 citations
5Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.2003 · 239 citations